



PORTOLA®
PHARMACEUTICALS

Portola Pharmaceuticals to Present at Cowen and Company 36th Annual Health Care Conference

March 1, 2016

SOUTH SAN FRANCISCO, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016, at 11:20 a.m. Eastern Time in Boston.

The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the [Investor Relations](#) section.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing its three wholly-owned programs using novel biomarker and genetic approaches that may increase the likelihood of clinical, regulatory and commercial success. These programs include betrixaban, an oral, once-daily Factor Xa inhibitor being evaluated in the APEX Phase 3 study for prophylaxis of venous thromboembolism; andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter [@Portola_Pharma](#).

Investor Contact:

Ana Kapor
Portola Pharmaceuticals
ir@portola.com

Media Contact:

Julie Normart
W2O Group
jnormart@w2ogroup.com



Portola Pharmaceuticals, Inc.